Submit to Molecules Review for Molecules Propose a Special Issue

Journal Browser

► Journal Browser

Metal Anticancer Complexes

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Inorganic Chemistry".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 50941

Share This Special Issue

Special Issue Editor

Dr. Kogularamanan Suntharalingam

E-Mail Website
Guest Editor

School of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, UK
Interests: metallopharmaceuticals; metallodrugs; biorganometallic complexes; biologically-active metal clusters; metal-based drug delivery agents; cancer metallomics; metal–protein interactions; metal–nucleic acid interactions; theranostics metal complexes; cancer imaging agents
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The identification of chemical agents with therapeutic potential is of high importance for research in bioinorganic chemistry and medicinal chemistry. Traditionally, organic molecules have dominated research in this area, and thus relatively little is known about the therapeutic properties of inorganic compounds. Despite breakthrough therapies for the treatment of cancer based on platinum, arsenic, and ruthenium compounds, metal complexes have received relatively little attention from the pharmaceutical industry and the chemical biology/medicinal chemistry research community as a whole. A number of small spinout companies have now started in-house research programs aimed at addressing key bioinorganic aspects of medicine; however, few large pharmaceutical companies have such mechanisms in place. The versatility of metal complexes, which arises from the choice of metal, oxidation state, redox activity, number and type of ligands, coordination geometry, and magnetic and optical properties, deserves to be investigated further in the context of rational drug design. This Special Issue of Molecules aims to showcase recent advancements in any aspect of metal-based anticancer therapeutics design and development. Synthetic, biophysical, in vitro, and in vivo studies are all welcome. Review articles that describe the current state of metal-based cancer therapeutics development, in any context, are also welcome.

Dr. Kogularamanan Suntharalingam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

metallopharmaceuticals
metallodrugs
biorganometallic complexes
biologically-active metal clusters
metal-based drug delivery agents
cancer metallomics
metal–protein interactions
metal–nucleic acid interactions
theranostics metal complexes
cancer imaging agents

Published Papers (13 papers)

Download All Papers

Research

Jump to: Review

12 pages, 6610 KiB

Open AccessArticle

DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands

by Mona S. Alsaeedi, Bandar A. Babgi, Magda H. Abdellattif, Abdesslem Jedidi, Mark G. Humphrey and Mostafa A. Hussien

Molecules 2021, 26(1), 76; https://doi.org/10.3390/molecules26010076 - 26 Dec 2020

Cited by 10 | Viewed by 2354

Abstract

Ruthenium(II) arene complexes of the general formula [RuCl(η⁶-p-cymene)(diamine)]PF₆ (diamine = 1,2-diaminobenzene (1), 2,3-diaminonaphthalene (2), 9,10-diaminophenanthrene (3), 2,3-diaminophenazine (4), and 1,2-diaminoanthraquinone (5) were synthesized. Chloro/aqua exchange was evaluated experimentally for complexes 1 and 2. The exchange process was investigated theoretically for all complexes, revealing relatively fast exchange with no significant influence from the polycyclic aromatic diamines. The calf thymus DNA (CT-DNA) binding of the complexes increased dramatically upon extending the aromatic component of the diamines, as evaluated by changes in absorption spectra upon titration with different concentrations of CT-DNA. An intercalation binding mode was established for the complexes using the increase in the relative viscosity of the CT-DNA following addition of complexes 1 and 2. Theoretical studies showed strong preference for replacement of water by guanine for all the complexes, and relatively strong Ru–N_guanine bonds. The plane of the aromatic systems can assume angles that support non-classical interactions with the DNA and covalent binding, leading to higher binding affinities. The ruthenium arenes illustrated in this study have promising anticancer activities, with the half maximal inhibitory concentration (IC₅₀) values comparable to or better than cisplatin against three cell lines. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

13 pages, 2303 KiB

Open AccessArticle

Synthesis, Characterization, and Antiproliferative Activity of Novel Chiral [QuinoxP*AuCl₂]⁺ Complexes

by Adedamola S. Arojojoye, R. Tyler Mertens, Samuel Ofori, Sean R. Parkin and Samuel G. Awuah

Molecules 2020, 25(23), 5735; https://doi.org/10.3390/molecules25235735 - 04 Dec 2020

Cited by 9 | Viewed by 2980

Abstract

Herein is reported the synthesis of two Au(III) complexes bearing the (R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxaline (R,R-QuinoxP*) or (S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)quinoxaline (S,S-QuinoxP*) ligands. By reacting two stoichiometric equivalents of HAuCl₄.3H₂O to one equivalent of the corresponding QuinoxP* ligand, (R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III) tetrachloroaurates(III) (1) and (S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III) tetrachloroaurates(III) (2) were formed, respectively, in moderate yields. The structure of (S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III) tetrachloroaurates(III) (2) was further confirmed by X-ray crystallography. The antiproliferative activities of the two compounds were evaluated in a panel of cell lines and exhibited promising results comparable to auranofin and cisplatin with IC₅₀ values between 1.08 and 4.83 µM. It is noteworthy that in comparison to other platinum and ruthenium enantiomeric complexes, the two enantiomers (1 and 2) do not exhibit different cytotoxic effects. The compounds exhibited stability in biologically relevant media over 48 h as well as inert reactivity to excess glutathione at 37 °C. These results demonstrate that the Au(III) atom, stabilized by the QuinoxP* ligand, can provide exciting compounds for novel anticancer drugs. These complexes provide a new scaffold to further develop a robust and diverse library of chiral phosphorus Au(III) complexes. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

18 pages, 3030 KiB

Open AccessArticle

Novel Papaverine Metal Complexes with Potential Anticancer Activities

by Ahmed Gaber, Walaa F. Alsanie, Deo Nandan Kumar, Moamen S. Refat and Essa M. Saied

Molecules 2020, 25(22), 5447; https://doi.org/10.3390/molecules25225447 - 20 Nov 2020

Cited by 53 | Viewed by 4730

Abstract

Cancer is one of the leading causes of death worldwide. Although several potential therapeutic agents have been developed to efficiently treat cancer, some side effects can occur simultaneously. Papaverine, a non-narcotic opium alkaloid, is a potential anticancer drug that showed selective antitumor activity in various tumor cells. Recent studies have demonstrated that metal complexes improve the biological activity of the parent bioactive ligands. Based on those facts, herein we describe the synthesis of novel papaverine–vanadium(III), ruthenium(III) and gold(III) metal complexes aiming at enhancing the biological activity of papaverine drug. The structures of the synthesized complexes were characterized by various spectroscopic methods (IR, UV–Vis, NMR, TGA, XRD, SEM). The anticancer activity of synthesized metal complexes was evaluated in vitro against two types of cancer cell lines: human breast cancer MCF-7 cells and hepatocellular carcinoma HepG-2 cells. The results revealed that papaverine-Au(III) complex, among the synthesized complexes, possess potential antimicrobial and anticancer activities. Interestingly, the anticancer activity of papaverine–Au(III) complex against the examined cancer cell lines was higher than that of the papaverine alone, which indicates that Au-metal complexation improved the anticancer activity of the parent drug. Additionally, the Au complex showed anticancer activity against the breast cancer MCF-7 cells better than that of cisplatin. The biocompatibility experiments showed that Au complex is less toxic than the papaverine drug alone with IC₅₀ ≈ 111 µg/mL. These results indicate that papaverine–Au(III) complex is a promising anticancer complex-drug which would make it a suitable candidate for further in vivo investigations. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

12 pages, 1897 KiB

Open AccessArticle

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents

by María Angeles Pujante-Galián, Sergio A. Pérez, Mercedes G. Montalbán, Guzmán Carissimi, Marta G. Fuster, Gloria Víllora and Gabriel García

Molecules 2020, 25(21), 5063; https://doi.org/10.3390/molecules25215063 - 31 Oct 2020

Cited by 15 | Viewed by 3637

Abstract

In this work, the cytotoxic behavior of six ruthenium(II) complexes of stoichiometry [(η⁶-p-cymene)RuCl₂L] (I-VI), L = 4-cyanopyridine (I), 2-aminophenol (II), 4-aminophenol (III), pyridazine (IV), and [(η⁶-p-cymene)RuClL₂]PF₆; L = cyanopyridine (V), L = 2-aminophenol(VI) towards three cell lines was studied. Two of them, HeLa and MCF-7, are human carcinogenic cells from cervical carcinoma and human breast cancer, respectively. A comparison with healthy cells was carried out with BGM cells which are monkey epithelial cells of renal origin. The behavior of complex II exhibits selectivity towards healthy cells, which is a promising feature for use in cancer treatment since it might reduce the side effects of most current therapies. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

13 pages, 2109 KiB

Open AccessCommunication

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

by Galina Kireeva, Stepan Kruglov, Mikhail Maydin, Ekaterina Gubareva, Elena Fedoros, Ekaterina Zubakina, Natalya Ivanenko, Marina Bezruchko and Nikolay Solovyev

Molecules 2020, 25(20), 4733; https://doi.org/10.3390/molecules25204733 - 15 Oct 2020

Cited by 3 | Viewed by 2007

Abstract

Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity profile of drugs under HIPEC. In the current study, 24 female Wistar rats were randomly assigned to receive cisplatin as HIPEC (n = 12, 20 mg/kg) or intravenously (i.v., n = 9, 4 mg/kg). The subgroups of three animals were used for the initial, intermediate, and late phases of the pharmacokinetic assessment. The animals were sacrificed on days 1 and 5. Blood, liver, kidney, and ovaries were evaluated for platinum content. Histological and immunohistochemical evaluation was undertaken in the liver and kidney. A trend for higher blood plasma platinum levels was observed for HIPEC compared to i.v. Significantly lower (p < 0.001) relative platinum binding to the proteins was observed in HIPEC animals compared to the i.v. administration. A five-fold higher concentration of cisplatin in HIPEC resulted in a ca. 2.5-fold increase in total blood platinum and ca. two-fold increase in blood ultrafitrable platinum (“free” Pt). Immunohistochemistry revealed higher kidney and liver damage after i.v. administration of cisplatin compared to HIPEC, although a five-fold higher dose of cisplatin was applied in HIPEC. Together with relatively lower absorption to the systemic circulation in HIPEC, higher protein binding is probably the primary reason for lower observed toxicity in HIPEC animals. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

20 pages, 4082 KiB

Open AccessArticle

Antitumor Activity of Ruthenium(II) Terpyridine Complexes towards Colon Cancer Cells In Vitro and In Vivo

by Maja Savic, Aleksandar Arsenijevic, Jelena Milovanovic, Bojana Stojanovic, Vesna Stankovic, Ana Rilak Simovic, Dejan Lazic, Nebojsa Arsenijevic and Marija Milovanovic

Molecules 2020, 25(20), 4699; https://doi.org/10.3390/molecules25204699 - 14 Oct 2020

Cited by 21 | Viewed by 3081

Abstract

Ruthenium complexes have attracted considerable interest as potential antitumor agents. Therefore, antitumor activity and systemic toxicity of ruthenium(II) terpyridine complexes were evaluated in heterotopic mouse colon carcinoma. In the present study, cytotoxic effects of recently synthesized ruthenium(II) terpyridine complexes [Ru(Cl-tpy)(en)Cl][Cl] (en = ethylenediamine, tpy = terpyridine, Ru-1) and [Ru(Cl-tpy)(dach)Cl][Cl] (dach = 1,2-diaminocyclohexane, Ru-2) towards human and murine colon carcinoma cells were tested in vitro and in vivo and compared with oxaliplatin, the most commonly used chemotherapeutic agent against colorectal carcinoma. Ruthenium(II) complexes showed moderate cytotoxicity with IC₅₀ values ranging between 19.1 to 167.3 μM against two human, HCT116 and SW480, and one mouse colon carcinoma cell line, CT26. Both ruthenium(II) terpyridine complexes exerted a moderate apoptotic effect in colon carcinoma cells, but induced significant necrotic death. Additionally, both complexes induced cell cycle disturbances, but these effects were specific for the cell line. Further, Ru-1 significantly reduced the growth of primary heterotopic tumor in mice, similarly to oxaliplatin. Renal damage in Ru-1 treated mice was lower in comparison with oxaliplatin treated mice, as evaluated by serum levels of urea and creatinine and histological evaluation, but Ru-1 induced higher liver damage than oxaliplatin, evaluated by the serum levels of alanine aminotransferase. Additionally, the interaction of these ruthenium(II) terpyridine complexes with the tripeptide glutathione (GSH) was investigated by proton nuclear magnetic resonance (¹H NMR) spectroscopy. All reactions led to the formation of monofunctional thiolate adducts [Ru(Cl-tpy)(en)GS-S] (3) and [Ru(Cl-tpy)(dach)GS-S] (4). Our data highlight the significant cytotoxic activity of [Ru(Cl-tpy)(en)Cl][Cl] against human and mouse colon carcinoma cells, as well as in vivo antitumor activity in CT26 tumor-bearing mice similar to standard chemotherapeutic oxaliplatin, accompanied with lower nephrotoxicity in comparison with oxaliplatin. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

16 pages, 2475 KiB

Open AccessArticle

Synthesis, Characterisation and In Vitro Anticancer Activity of Catalytically Active Indole-Based Half-Sandwich Complexes

by Joan J. Soldevila-Barreda, Kehinde B. Fawibe, Maria Azmanova, Laia Rafols, Anaïs Pitto-Barry, Uche B. Eke and Nicolas P. E. Barry

Molecules 2020, 25(19), 4540; https://doi.org/10.3390/molecules25194540 - 03 Oct 2020

Cited by 12 | Viewed by 2992

Abstract

The synthesis, characterisation and evaluation of the in vitro cytotoxicity of four indole-based half-sandwich metal complexes towards two ovarian cancer cell lines (A2780 and A2780cisR) and one normal prostate cell line (PNT2) are presented herein. Although capable of inducing catalytic oxidation of NADH and able to reduce NAD⁺ with high turnover frequencies, in cells and in the presence of sodium formate, these complexes also strongly interact with biomolecules such as glutathione. This work highlights that efficient out-of-cells catalytic activity might lead to higher reactivity towards biomolecules, thus inhibiting the in-cells catalytic processes. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

8 pages, 1258 KiB

Open AccessArticle

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity

by Jasmine M. Cross, Tim R. Blower, Alexander D. H. Kingdon, Robert Pal, David M. Picton and James W. Walton

Molecules 2020, 25(10), 2383; https://doi.org/10.3390/molecules25102383 - 21 May 2020

Cited by 8 | Viewed by 4438

Abstract

The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms may lead to unwanted side-effects. In this paper, we show that piano stool Ru complexes can act as HDAC inhibitors, and variation in the capping arene leads to differences in HDAC isoform selectivity. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

19 pages, 2417 KiB

Open AccessFeature PaperArticle

The Application of Reversible Intramolecular Sulfonamide Ligation to Modulate Reactivity in Organometallic Ruthenium(II) Diamine Complexes

by Samuel A. Kemp, Timothy J. Prior, Huguette Savoie, Ross W. Boyle and Benjamin S. Murray

Molecules 2020, 25(2), 244; https://doi.org/10.3390/molecules25020244 - 07 Jan 2020

Cited by 4 | Viewed by 2834

Abstract

Metallation of biomacromolecular species forms the basis for the anticancer activity of many metallodrugs. A major limitation of these compounds is that their reactivity is indiscriminate and can, in principle, occur in healthy tissue as well as cancerous tissue, potentially leading to side effects in vivo. Here we present pH-dependent intramolecular coordination of an arene-tethered sulfonamide functionality in organometallic ruthenium(II) ethylenediamine complexes as a route to controlling the coordination environment about the central metal atom. Through variation of the sulfonamide R group and the length of the tether linking it to the arene ligand the acidity of the sulfonamide NH group, and hence the pH-region over which regulation of metal coordination occurs, can be modulated. Intramolecular sulfonamide ligation controlled the reactivity of complex 4 within the physiologically relevant pH-region, rendering it more reactive towards 5ʹ-GMP in mildly acidic pH-conditions typical of tumour tissue compared to the mildly alkaline pH-conditions typical of healthy tissue. However, the activation of 4 by ring-opening of the chelate was found to be a slow process relative to the timescale of typical cell culture assays and members of this series of complexes were found not to be cytotoxic towards the HT-29 cell line. These complexes provide the basis for the development of analogues of increased potency where intramolecular sulfonamide ligation regulates reactivity and therefore cytotoxicity in a pH-dependent, and potentially, tissue-dependent manner. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

9 pages, 700 KiB

Open AccessFeature PaperCommunication

Modulating the Chemical and Biological Properties of Cancer Stem Cell-Potent Copper(II)-Nonsteroidal Anti-Inflammatory Drug Complexes

by Jimin Shin, Arvin Eskandari and Kogularamanan Suntharalingam

Molecules 2019, 24(9), 1677; https://doi.org/10.3390/molecules24091677 - 29 Apr 2019

Cited by 9 | Viewed by 3875

Abstract

Copper(II) complexes bearing nonsteroidal anti-inflammatory drugs (NSAIDs) are known to potently kill cancer stem cells (CSCs), a subpopulation of tumour cells with high metastatic and relapse fidelity. One of the major disadvantages associated to these copper(II) complexes is their instability in the presence of strong cellular reductants (such as ascorbic acid). Here we present a biologically stable copper(II)-NSAID complex containing a bathocuproinedisulfonic acid disodium ligand and two indomethacin moieties, Cu(bathocuproinedisulfonic acid disodium)(indomethacin)₂, 2. The copper(II) complex, 2 kills bulk breast cancer cells and breast CSC equally (in the sub-micromolar range) and displays very low toxicity against non-tumorigenic breast and kidney cells (IC₅₀ value > 100 µM). Three-dimensional cell culture studies show that 2 can significantly reduce the number and size of breast CSC mammospheres formed (from single suspensions) to a similar level as salinomycin (an established anti-breast CSC agent). The copper(II) complex, 2 is taken up reasonably by breast CSCs and localises largely in the cytoplasm (>90%). Cytotoxicity studies in the presence of specific inhibitors suggest that 2 induces CSC death via a reactive oxygen species (ROS) and cyclooxygenase isoenzyme-2 (COX-2) dependent apoptosis pathway. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

Review

Jump to: Research

36 pages, 1545 KiB

Open AccessReview

Endoplasmic Reticulum Stress Provocation by Different Nanoparticles: An Innovative Approach to Manage the Cancer and Other Common Diseases

by Amjad Ali Khan, Khaled S. Allemailem, Ahmad Almatroudi, Saleh A. Almatroodi, Ali Mahzari, Mohammed A. Alsahli and Arshad Husain Rahmani

Molecules 2020, 25(22), 5336; https://doi.org/10.3390/molecules25225336 - 16 Nov 2020

Cited by 25 | Viewed by 4477

Abstract

A proper execution of basic cellular functions requires well-controlled homeostasis including correct protein folding. Endoplasmic reticulum (ER) implements such functions by protein reshaping and post-translational modifications. Different insults imposed on cells could lead to ER stress-mediated signaling pathways, collectively called the unfolded protein response (UPR). ER stress is also closely linked with oxidative stress, which is a common feature of diseases such as stroke, neurodegeneration, inflammation, metabolic diseases, and cancer. The level of ER stress is higher in cancer cells, indicating that such cells are already struggling to survive. Prolonged ER stress in cancer cells is like an Achilles’ heel, if aggravated by different agents including nanoparticles (NPs) may be exhausted off the pro-survival features and can be easily subjected to proapoptotic mode. Different types of NPs including silver, gold, silica, graphene, etc. have been used to augment the cytotoxicity by promoting ER stress-mediated cell death. The diverse physico-chemical properties of NPs play a great role in their biomedical applications. Some special NPs have been effectively used to address different types of cancers as these particles can be used as both toxicological or therapeutic agents. Several types of NPs, and anticancer drug nano-formulations have been engineered to target tumor cells to enhance their ER stress to promote their death. Therefore, mitigating ER stress in cancer cells in favor of cell death by ER-specific NPs is extremely important in future therapeutics and understanding the underlying mechanism of how cancer cells can respond to NP induced ER stress is a good choice for the development of novel therapeutics. Thus, in depth focus on NP-mediated ER stress will be helpful to boost up developing novel pro-drug candidates for triggering pro-death pathways in different cancers. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

23 pages, 2053 KiB

Open AccessReview

Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy

by Hui Shan Liew, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Nicolas Delsuc and May Lee Low

Molecules 2020, 25(18), 4176; https://doi.org/10.3390/molecules25184176 - 12 Sep 2020

Cited by 44 | Viewed by 5168

Abstract

Photodynamic therapy (PDT) is emerging as a significant complementary or alternative approach for cancer treatment. PDT drugs act as photosensitisers, which upon using appropriate wavelength light and in the presence of molecular oxygen, can lead to cell death. Herein, we reviewed the general characteristics of the different generation of photosensitisers. We also outlined the emergence of rhenium (Re) and more specifically, Re(I) tricarbonyl complexes as a new generation of metal-based photosensitisers for photodynamic therapy that are of great interest in multidisciplinary research. The photophysical properties and structures of Re(I) complexes discussed in this review are summarised to determine basic features and similarities among the structures that are important for their phototoxic activity and future investigations. We further examined the in vitro and in vivo efficacies of the Re(I) complexes that have been synthesised for anticancer purposes. We also discussed Re(I) complexes in conjunction with the advancement of two-photon PDT, drug combination study, nanomedicine, and photothermal therapy to overcome the limitation of such complexes, which generally absorb short wavelengths. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Figure 1

25 pages, 1696 KiB

Open AccessFeature PaperReview

Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

by Golara Golbaghi and Annie Castonguay

Molecules 2020, 25(2), 265; https://doi.org/10.3390/molecules25020265 - 09 Jan 2020

Cited by 56 | Viewed by 7640

Abstract

Since the discovery of the anticancer potential of ruthenium-based complexes, several species were reported as promising candidates for the treatment of breast cancer, which accounts for the greatest number of new cases in women every year worldwide. Among these ruthenium complexes, species containing bioactive ligand(s) have attracted increasing attention due to their potential multitargeting properties, leading to anticancer drug candidates with a broader range of cellular targets/modes of action. This review of the literature aims at providing an overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)). In addition, this brief survey highlights some of the most successful examples of ruthenium complexes reported for the treatment of triple negative breast cancer (TNBC), a highly aggressive type of cancer, regardless of if their ligands are known to have the ability to achieve a specific biological function. Full article

(This article belongs to the Special Issue Metal Anticancer Complexes)

► Show Figures

Graphical abstract

Journal Menu

Journal Browser

Metal Anticancer Complexes

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (13 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI